Long-circulating doxorubicin and Schizandrin A liposome with drug-resistant liver cancer activity: in vitro and in vivo evaluation

References

• Forner, A., Reig, MÃ., and Bruix, J., 2018. Hepatocellular carcinoma. The lancet, 391 (10127), 1301–1314.
   PubMed Web of Science ®Google Scholar
• Bartlett, J.J., et al., 2016. Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy. Biochemical journal, 473 (21), 3769–3789.
   PubMed Web of Science ®Google Scholar
• Brown, D.I. and Griendling, K.K., 2015. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circulation research, 116 (3), 531–549.
   PubMed Web of Science ®Google Scholar
• Cao, Z.G. and Yuan, S.J., 2003. Research progress on inhibition of Bax gene expression and cell protection. Chinese journal of clinical pharmacology and therapeutics, 8 (3), 245–248.
   Google Scholar
• Feng, Y.M., 2020. Combined and comparative study of multiple treatments for hepatocellular carcinoma. PhD dissertation. Shandong University.
   Google Scholar
• Bruix, J., et al., 2015. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Oncology, 16 (13), 1344–1354.
   PubMed Web of Science ®Google Scholar
• Huang, B.C. and Long, X.D., 2012. Research progress of Bcl-2 and Bax protein in hepatocellular carcinoma. Journal of qiqihar medical college, 33 (03), 355–356.
   Google Scholar
• Hu, X.J., Su, F., and He, G.W., 2015. Research Progress on long-circulating liposomes in targeted drug delivery systems. Anhui Medical and Pharmaceutical Journal, 19 (10), 1837–1840.
   Google Scholar
• Lai, S.Z., Zhao, X.Z., Wang, J.Y., et al., 2021. Research progress in Schisandrin A inhibiting tumor growth and the mechanism of metastasis. Chinese Journal of Surgery of Integrated Traditional and Western Medicine, 27 (06), 928–931.
   Google Scholar
• Lawal, G., Xiao, Y., Rahnemai-Azar, A.A., et al., 2021. The Immunology of Hepatocellular Carcinoma. Vaccines (Basel).15, 9 (10), 1184.
   Google Scholar
• Liang SB, 2017.Research Progress in molecular targeting and chemotherapeutic drugs in hepatocellular carcinoma. Chinese Journal of Internal Medicine, 12 (04): 498–500 + 504.
   Google Scholar
• Li T, Tang RW, Yuan S, et al.,2020. Study on the mechanism of formononetin inhibition of autophagy-reverse hormone receptor-positive human breast cancer cells. Shanghai Journal of Traditional Chinese Medicine, 54(S1):147–152.
   Google Scholar
• Liu YY, Huang SQ, Li YZ, et al., 2022. Research progress on the chemical compositionsand their pharmacological effects on lignans from Schisandra plants. Chinese Herbal Medicines, 53(06):1903–1918.
   Google Scholar
• Li J, Zhang P, Li WY, et al., 2020. Research progress of Schisandra methylcin. China Pharmaceuticals, 29(5): 53–56.
   Google Scholar
• Llovet JM, Pinyol R, Kelley RK, et al., 2022. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. Apr;3(4):386–401.
   Google Scholar
• Mohamed Saeed et al., 2015. Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking. The Journal of Nutritional Biochemistry, 26(1) : 44–56.
   Google Scholar
• McGlynn KA, Petrick J L, London W T, 2015. Global Epidemiologyof Hepatocellular Carcinoma: An Emphasis on Demographic and Regional Variability. Clinics in liver disease, 19(2): 223–238.
   PubMed Web of Science ®Google Scholar
• Ning, Y.M., Pan, Y.F., and Li, F.Z., 2021. Study of multidrug resistance reversal effect and mechanism of tanshinoneII A on doxorubicin-resistant human breast cancer cells. Chinese Herbal Medicines, 52 (22), 6890–6896.
   Google Scholar
• Nitiss J L, 2009. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews Cancer, 9(5): 338–350.
   Google Scholar
• Peng J, Fumoto S, Miyamoto H, et al., 2017. One-step formationof lipid-polyacrylic acid-calcium carbonate nanoparticles for co-delivery of doxorubicin andcurcumin. J Drug Target, Sep;25 (8):704–714.
   Google Scholar
• Qin XQ, Liang YG, Gao HZ, et al., 2011. Study of the reversal mechanism of Schisandrin A on multidrug resistance against K562/ADR,HL60/ADR, and MCF-7/ADR. Chinese Pharmacological Bulletin ,27 (03):329–334.
   Google Scholar
• Rivankar S, 2014. An overview of doxorubicin formulations in cancer therapy. Journal of Cancer Research & Therapeutics, 10(4): 853–858.
   Google Scholar
• Shen M, 2019. Effect of Platycodon grandiflorum combined with doxorubicin in the treatment of lung metastasis of breast cancer in mice and its pharmacokinetics. Shanghai University of traditional Chinese medicine,Master's thesis.
   Google Scholar
• Shi JF, Luo YY, Li JX, et al., 2019. Research progress on the anti-tumor effect and mechanism of triptolide monotherapy and combination drugs. China Journal of Chinese Materia Medica, 44 (16): 3391–3398.
   Google Scholar
• Shi JF, Li J, Yang XQ, et al.,2019. Analysis on the current situation of nano co loading system combined with anti-tumor of active components of traditional Chinese medicine and chemotherapeutic drugs, Acta Pharmaceutica Sinica B,54 (02): 258–268.
   Google Scholar
• Sowndhararajan K, Deepa P, Kim M, et al., 2018. An overview of neuroprotective and cognitive enhancement properties of lignans from Schisandra chinensis. Biomedicine & Pharmacotherapy, 97: 958–968.
   Google Scholar
• Sun HC, Xie Q, Jia WD, et al., 2021. Consensus of Chinese experts on transformation and treatment of Liver Cancer (2021 Edition). Chinese Journal of Practical Surgery,41(06):618–632.
   Google Scholar
• Tomonori K, Genzou T, Hiromitsu K, et al., 2012. Prior starvation mitigates acute doxorubicin cardiotoxicity through restorationof autophagy in affected cardiomyocytes. Cardiovascular Research, 96: 456–465.
   Google Scholar
• Varela-López A, Battino M, Navarro-Hortal M D, et al., 2019. An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients. Food and Chemical Toxicology, 134: 110834.
   Google Scholar
• Vincent, D.T., et al., 2013. The role of antioxidants in the era of cardio-oncology. Cancer chemotherapy and pharmacology, 72 (6), 1157–1168.
   PubMed Web of Science ®Google Scholar
• Wang X, 2021. Study on doxorubicin metabolism and action targets in tumor cells. PhD dissertation. Jiangnan University.
   Google Scholar
• Wang, H.F., et al., 2021. Effects of lentinan combined with doxorubicin on apoptosis and drug resistance gene expression of gastric cancer SGC7901 cells. China food safety magazine, (25), 114–116.
   Google Scholar
• Wang XP, 2020. DanQiPian and tanshinone IIA regulate mtor-ulk1/TFEB autophagy pathway to protect adriamycin induced myocardial injury. Master’s thesis. Beijing University of Traditional Chinese Medicine.
   Google Scholar
• Weng, P.H., 2021. Ultrasound-microbubble-mediated miR-128 inhibited doxorubicin resistance in breast cancer cells by regulating PTEN. Guangzhou medical journal, 52 (06), 35–38.
   Google Scholar
• Xian, H.B, 2020. Mechanism study of Schizandra methylcin delaying NSCLC gefitinib resistance by inhibiting the IKKβ/NF-κB pathway. PhD dissertation. Southern Medical University.
   Google Scholar
• Xiao, X. and Xu, L., 2021. Research progress of traditional Chinese medicine compound combined with chemotherapeutic drugs/molecular targeted drugs in the treatment of lung cancer. Guiding journal of traditional Chinese medicine and pharmacy, 27 (10), 138–141.
   Google Scholar
• Xing, N.N., et al., 2021. Research progress on main chemical constituents and modern pharmacological effects of Schisandra Chinensis. Chinese journal of experimental traditional medical formulae, 27 (15), 210–218.
   Google Scholar
• Xue, Y., et al., 2020. Schisandrin a combined with gemcitabine inhibits the proliferation of hepatoma cell line HepG2. Chinese pharmacological bulletin, 36 (04), 550–555.
   Google Scholar
• Xue, J.X., et al., 2018. The traditional Chinese medicine Kangai injection as an adjuvant method in combination with chemotherapy for the treatment of breast cancer in Chinese patients: a meta-analysis. Evidence-based complementary and alternative medicine, 2018, 6305645.
   PubMed Web of Science ®Google Scholar
• Xu, S.Y., et al., 2021. Long-circulating doxorubicin and Schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. Journal of liposome research, 13, 1–12.
   Google Scholar
• Yang, Z., et al., 2017. PH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. Biomaterials, 147, 53–67.
   PubMed Web of Science ®Google Scholar
• Zhai, L.H. and Lu, H.B., 2020. Drug therapy for advanced primary hepatocellular carcinoma. Journal of modern oncology, 28 (02), 326–329.
   Google Scholar
• Zhang, Y.Y., et al., 2021. Effects of Notch1 regulating PTEN expression on stem and doxorubicin resistance in non-small cell lung cancer cells. Journal of Shanxi Medical University, 52 (10), 1247–1253.
   Google Scholar
• Zhou, J., et al., 2020. Guidelines for the diagnosis and treatment of Hepatocellular Carcinoma (2019 Edition). Liver cancer, 9 (6), 682–720.
   PubMed Web of Science ®Google Scholar